U.S.-China trade agreement; CPI ahead this week - what’s moving markets By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2025
0mins
Source: Investing.com
U.S.-China Trade Agreement: U.S. stock futures surged after the announcement of a significant reduction in tariffs between the U.S. and China, with both countries agreeing to a 90-day pause on escalating tariffs, which has alleviated investor concerns about a potential global economic crisis.
Impact on Pharmaceutical Stocks: Pharmaceutical stocks declined following President Trump's plan to sign an executive order aimed at reducing drug prices by aligning U.S. costs with those in other high-income countries, potentially affecting the profitability of international drugmakers reliant on the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 44.740
Low
42.00
Averages
54.67
High
70.00
Current: 44.740
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Shares Continue Underperformance Amid Competition
- Poor Stock Performance: Novo Nordisk's shares have declined by 7.5% this year, contrasting with the S&P 500's 8% gain, indicating a lack of competitive strength in the market and suggesting investors should carefully assess holding risks.
- High Sales Dependency: The company's weight loss drug Wegovy and diabetes treatment Ozempic accounted for over 75% of first-quarter sales, highlighting a significant reliance on these products, which could impact future performance.
- Intensifying Competition: Despite Novo Nordisk launching a Wegovy pill, its sales are pressured by competitors like Eli Lilly, which received FDA approval for the oral treatment Foundayo, leading to an 8% year-over-year decline in Ozempic's first-quarter sales.
- Uncertain Market Outlook: With fierce competition from companies like Pfizer, Novo Nordisk's dominance in the obesity and diabetes market is threatened, prompting a recommendation for investors to consider selling their shares to mitigate potential risks.
See More
AstraZeneca Secures FDA Approval for Baxfendy, Targeting $5 Billion Sales
- Drug Approval: AstraZeneca's hypertension medication Baxfendy has received FDA approval, potentially becoming a significant growth driver with projected annual sales exceeding $5 billion, particularly for patients inadequately treated by existing therapies.
- Market Opportunity: Clinical trials demonstrated that Baxfendy significantly lowers blood pressure when used alongside other antihypertensives, addressing the urgent need for effective treatments among approximately 23 million patients in the U.S. who still struggle with blood pressure control.
- Strategic Acquisition: Baxfendy was acquired through AstraZeneca's $1.8 billion purchase of CinCor Pharma in 2023, highlighting the company's strategic focus on cardiovascular and metabolic diseases while enhancing its competitive position in the rapidly growing weight-loss market.
- Future Prospects: AstraZeneca is also testing Baxfendy for heart failure prevention, which could further propel the company towards its ambitious goal of achieving $80 billion in annual revenue by 2030, reflecting a long-term strategic vision in drug development.
See More
Novo Nordisk Goes All In on Wegovy Global Launch
- Global Market Expansion: Novo Nordisk is preparing to launch the Wegovy pill outside the U.S., with expectations to start later this year, although specific countries remain unspecified; the decision will be based on patient interest and physician training, thus seizing growth opportunities in the global weight-loss drug market.
- Sales Forecast Adjustment: Despite over 2 million prescriptions for Wegovy in the U.S. exceeding expectations in its first quarter, Novo forecasts a decline in sales and profits between 4% and 12% by 2026, primarily due to lower prices in the U.S. and generic competition in markets like India and Canada.
- Changing Competitive Landscape: The rivalry between Novo and Eli Lilly intensifies, with Lilly expecting a 28% sales growth this year while Novo faces downward pressure on sales, highlighting the fierce competition for market share in the weight-loss sector.
- Patient Access Channels: Novo emphasizes broadening patient access to Wegovy through telehealth, particularly in Germany, where the convenience of telehealth has made it easier for patients to receive treatment, reflecting the company's sensitivity and adaptability to patient needs in the global market.
See More
Novo Nordisk Aims to Close Gap with Eli Lilly in Weight-Loss Market
- Intensifying Market Competition: Despite Novo Nordisk's first-mover advantage in the weight-loss drug market, Eli Lilly's Zepbound saw an 80% year-over-year sales increase, threatening Novo's market position and prompting the launch of an oral version of Wegovy to cater to patient preferences for oral treatments, thereby enhancing its competitive stance.
- New Drug Development Updates: Eli Lilly launched its own weight-loss pill, Foundayo, in April and is developing a triple agonist, retatrutide, targeting GLP-1, GIP, and glucagon receptors, which could further solidify its market dominance and increase pressure on Novo Nordisk.
- Clinical Trial Results: Eli Lilly's promising phase 3 clinical trial data for retatrutide, released in March, showed significant reductions in A1C and weight loss among participants, establishing a strong foundation for its future market performance and potentially keeping its stock elevated.
- Market Valuation Outlook: Although Eli Lilly's stock trades above $1,000 with a price-to-earnings ratio exceeding 26, if its follow-up products maintain market superiority, investors will likely continue to view it as a top GLP-1 stock, supporting its premium valuation.
See More
Kailera Therapeutics Makes Successful IPO Amid Biotech Surge
- IPO Pricing and Market Reaction: Kailera Therapeutics priced its initial public offering (IPO) at $16 per share, opening at $26 on April 17; although the stock price has recently cooled, its promising drug pipeline continues to attract investor interest.
- Market Potential Analysis: According to Morgan Stanley research, the GLP-1 drug market aimed at weight loss could reach $190 billion by 2035, doubling the levels of 2025, significantly enhancing Kailera's competitive position in this lucrative market.
- Drug Development Progress: Kailera is building a weight-loss drug pipeline with both injectables and pills, featuring four candidates in various trial stages, with its lead candidate Ribupatide currently in phase 3 trials, potentially becoming a category-leading treatment for obesity.
- Investment Risks and Opportunities: While biotech investments are notoriously risky, Kailera's advanced drug candidates in clinical trials present a fresh investment opportunity, particularly for aggressive investors willing to navigate potential setbacks, as the long-term rewards may outweigh the risks.
See More
Hims & Hers Reports Revenue Growth Amid Shrinking Margins
- Revenue Growth: Hims & Hers reported first-quarter 2026 revenue of $608.1 million, a 4% year-over-year increase, indicating continued subscriber growth across its weight-loss, sexual health, dermatology, and primary care sectors, despite profitability challenges.
- Profit Decline: The company posted a net loss of $92.1 million compared to a net income of $49.5 million a year earlier, with adjusted EBITDA falling from $91.1 million to $44.3 million and gross margin shrinking from 73% to 65%, highlighting the economic pressures from its strategic shift.
- Strategic Shift: Hims transitioned from high-margin compounded GLP-1 weight-loss drugs to branded products like Novo Nordisk's, which reduced regulatory risks but compressed margins and increased operating costs, resulting in a more than 12% drop in stock price following the earnings release.
- International Expansion: The acquisition of ZAVA allows Hims to tap into the European market with approximately $100 million in annual revenue and an established telemedicine infrastructure, while the company plans to expand into hormone optimization and preventative diagnostics, despite facing high valuation and execution risks.
See More
Novo Nordisk Shares Continue Underperformance Amid Competition
- Poor Stock Performance: Novo Nordisk's shares have declined by 7.5% this year, contrasting with the S&P 500's 8% gain, indicating a lack of competitive strength in the market and suggesting investors should carefully assess holding risks.
- High Sales Dependency: The company's weight loss drug Wegovy and diabetes treatment Ozempic accounted for over 75% of first-quarter sales, highlighting a significant reliance on these products, which could impact future performance.
- Intensifying Competition: Despite Novo Nordisk launching a Wegovy pill, its sales are pressured by competitors like Eli Lilly, which received FDA approval for the oral treatment Foundayo, leading to an 8% year-over-year decline in Ozempic's first-quarter sales.
- Uncertain Market Outlook: With fierce competition from companies like Pfizer, Novo Nordisk's dominance in the obesity and diabetes market is threatened, prompting a recommendation for investors to consider selling their shares to mitigate potential risks.
See More
AstraZeneca Secures FDA Approval for Baxfendy, Targeting $5 Billion Sales
- Drug Approval: AstraZeneca's hypertension medication Baxfendy has received FDA approval, potentially becoming a significant growth driver with projected annual sales exceeding $5 billion, particularly for patients inadequately treated by existing therapies.
- Market Opportunity: Clinical trials demonstrated that Baxfendy significantly lowers blood pressure when used alongside other antihypertensives, addressing the urgent need for effective treatments among approximately 23 million patients in the U.S. who still struggle with blood pressure control.
- Strategic Acquisition: Baxfendy was acquired through AstraZeneca's $1.8 billion purchase of CinCor Pharma in 2023, highlighting the company's strategic focus on cardiovascular and metabolic diseases while enhancing its competitive position in the rapidly growing weight-loss market.
- Future Prospects: AstraZeneca is also testing Baxfendy for heart failure prevention, which could further propel the company towards its ambitious goal of achieving $80 billion in annual revenue by 2030, reflecting a long-term strategic vision in drug development.
See More
Novo Nordisk Goes All In on Wegovy Global Launch
- Global Market Expansion: Novo Nordisk is preparing to launch the Wegovy pill outside the U.S., with expectations to start later this year, although specific countries remain unspecified; the decision will be based on patient interest and physician training, thus seizing growth opportunities in the global weight-loss drug market.
- Sales Forecast Adjustment: Despite over 2 million prescriptions for Wegovy in the U.S. exceeding expectations in its first quarter, Novo forecasts a decline in sales and profits between 4% and 12% by 2026, primarily due to lower prices in the U.S. and generic competition in markets like India and Canada.
- Changing Competitive Landscape: The rivalry between Novo and Eli Lilly intensifies, with Lilly expecting a 28% sales growth this year while Novo faces downward pressure on sales, highlighting the fierce competition for market share in the weight-loss sector.
- Patient Access Channels: Novo emphasizes broadening patient access to Wegovy through telehealth, particularly in Germany, where the convenience of telehealth has made it easier for patients to receive treatment, reflecting the company's sensitivity and adaptability to patient needs in the global market.
See More
Novo Nordisk Aims to Close Gap with Eli Lilly in Weight-Loss Market
- Intensifying Market Competition: Despite Novo Nordisk's first-mover advantage in the weight-loss drug market, Eli Lilly's Zepbound saw an 80% year-over-year sales increase, threatening Novo's market position and prompting the launch of an oral version of Wegovy to cater to patient preferences for oral treatments, thereby enhancing its competitive stance.
- New Drug Development Updates: Eli Lilly launched its own weight-loss pill, Foundayo, in April and is developing a triple agonist, retatrutide, targeting GLP-1, GIP, and glucagon receptors, which could further solidify its market dominance and increase pressure on Novo Nordisk.
- Clinical Trial Results: Eli Lilly's promising phase 3 clinical trial data for retatrutide, released in March, showed significant reductions in A1C and weight loss among participants, establishing a strong foundation for its future market performance and potentially keeping its stock elevated.
- Market Valuation Outlook: Although Eli Lilly's stock trades above $1,000 with a price-to-earnings ratio exceeding 26, if its follow-up products maintain market superiority, investors will likely continue to view it as a top GLP-1 stock, supporting its premium valuation.
See More
Kailera Therapeutics Makes Successful IPO Amid Biotech Surge
- IPO Pricing and Market Reaction: Kailera Therapeutics priced its initial public offering (IPO) at $16 per share, opening at $26 on April 17; although the stock price has recently cooled, its promising drug pipeline continues to attract investor interest.
- Market Potential Analysis: According to Morgan Stanley research, the GLP-1 drug market aimed at weight loss could reach $190 billion by 2035, doubling the levels of 2025, significantly enhancing Kailera's competitive position in this lucrative market.
- Drug Development Progress: Kailera is building a weight-loss drug pipeline with both injectables and pills, featuring four candidates in various trial stages, with its lead candidate Ribupatide currently in phase 3 trials, potentially becoming a category-leading treatment for obesity.
- Investment Risks and Opportunities: While biotech investments are notoriously risky, Kailera's advanced drug candidates in clinical trials present a fresh investment opportunity, particularly for aggressive investors willing to navigate potential setbacks, as the long-term rewards may outweigh the risks.
See More
Hims & Hers Reports Revenue Growth Amid Shrinking Margins
- Revenue Growth: Hims & Hers reported first-quarter 2026 revenue of $608.1 million, a 4% year-over-year increase, indicating continued subscriber growth across its weight-loss, sexual health, dermatology, and primary care sectors, despite profitability challenges.
- Profit Decline: The company posted a net loss of $92.1 million compared to a net income of $49.5 million a year earlier, with adjusted EBITDA falling from $91.1 million to $44.3 million and gross margin shrinking from 73% to 65%, highlighting the economic pressures from its strategic shift.
- Strategic Shift: Hims transitioned from high-margin compounded GLP-1 weight-loss drugs to branded products like Novo Nordisk's, which reduced regulatory risks but compressed margins and increased operating costs, resulting in a more than 12% drop in stock price following the earnings release.
- International Expansion: The acquisition of ZAVA allows Hims to tap into the European market with approximately $100 million in annual revenue and an established telemedicine infrastructure, while the company plans to expand into hormone optimization and preventative diagnostics, despite facing high valuation and execution risks.
See More
